| XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer J Kim, E McMillan, HS Kim, N Venkateswaran, G Makkar, ... Nature 538 (7623), 114-117, 2016 | 198 | 2016 |
| Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer HS Kim, S Mendiratta, J Kim, CV Pecot, JE Larsen, I Zubovych, BY Seo, ... Cell 155 (3), 552-566, 2013 | 193 | 2013 |
| Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan C Wang, H Niederstrasser, PM Douglas, R Lin, J Jaramillo, Y Li, ... Nature communications 8 (1), 2270, 2017 | 138 | 2017 |
| Chemistry-first approach for nomination of personalized treatment in lung cancer EA McMillan, MJ Ryu, CH Diep, S Mendiratta, JR Clemenceau, ... Cell 173 (4), 864-878. e29, 2018 | 116 | 2018 |
| Using functional signature ontology (FUSION) to identify mechanisms of action for natural products MB Potts, HS Kim, KW Fisher, Y Hu, YP Carrasco, GB Bulut, YH Ou, ... Science signaling 6 (297), ra90-ra90, 2013 | 86 | 2013 |
| Biomarker accessible and chemically addressable mechanistic subtypes of BRAF melanoma B Eskiocak, EA McMillan, S Mendiratta, RK Kollipara, H Zhang, ... Cancer discovery 7 (8), 832-851, 2017 | 60 | 2017 |
| Host modulators of H1N1 cytopathogenicity SE Ward, HS Kim, K Komurov, S Mendiratta, PL Tsai, M Schmolke, ... Public Library of Science 7 (8), e39284, 2012 | 40 | 2012 |
| Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer A Servetto, R Kollipara, L Formisano, CC Lin, KM Lee, DR Sudhan, ... Clinical Cancer Research 27 (15), 4379-4396, 2021 | 38 | 2021 |
| Exploiting the CRISPR/Cas9 PAM constraint for single-nucleotide resolution interventions Y Li, S Mendiratta, K Ehrhardt, N Kashyap, MA White, L Bleris PloS one 11 (1), e0144970, 2016 | 33 | 2016 |
| RASSF1A inactivation unleashes a tumor suppressor/oncogene cascade with context-dependent consequences on cell cycle progression RR Ram, S Mendiratta, BO Bodemann, MJ Torres, U Eskiocak, MA White Molecular and cellular biology 34 (12), 2350-2358, 2014 | 24 | 2014 |
| Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple-negative breast cancer K Lee, CC Lin, A Servetto, J Bae, V Kandagatla, D Ye, GM Kim, ... Cancer immunology research 10 (7), 829-843, 2022 | 16 | 2022 |
| Synthesis and structure–activity studies of the V-ATPase inhibitor saliphenylhalamide (SaliPhe) and simplified analogs J Garcia-Rodriguez, S Mendiratta, MA White, XS Xie, JK De Brabander Bioorganic & medicinal chemistry letters 25 (20), 4393-4398, 2015 | 16 | 2015 |
| A genome-wide functional signature ontology map and applications to natural product mechanism of action discovery EA McMillan, G Kwon, JR Clemenceau, KW Fisher, RM Vaden, AF Shaikh, ... Cell chemical biology 26 (10), 1380-1392. e6, 2019 | 7 | 2019 |
| Author Correction: Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan C Wang, H Niederstrasser, PM Douglas, R Lin, J Jaramillo, Y Li, ... Nature communications 9, 2018 | 5 | 2018 |
| Natural Language Query in the Biochemistry and Molecular Biology Domains Based on Cognition Search™ EJ Goldsmith, S Mendiratta, R Akella, K Dahlgren Summit on Translational Bioinformatics 2009, 32, 2009 | 5 | 2009 |
| A platform of CDK4/6 inhibitor-resistant patient-derived breast cancer organoids illuminates mechanisms of resistance and therapeutic vulnerabilities ABH Hanker, S Chatterjee, Y Wang, D Ye, DR Sudhan, BM Larsen, ... AACR; Cancer Res 82 (4 Suppl), Abstract nr PD2-01, 2022 | 1 | 2022 |
| Abstract PS17-09: An FGFR1/2 degrader overcomes antiestrogen resistance in ER+/FGFR1-amplified breast cancer Y Uemoto, CC Lin, A Servetto, B Wang, D Ye, F Napolitano, HM Patel, ... Cancer Research 84 (9_Supplement), PS17-09-PS17-09, 2024 | | 2024 |
| Abstract PS03-04: Tumor immune microenvironment modulates resistance to estrogen suppression in ER+ breast cancer F Napolitano, Y Wang, D Sudhan, P Gonzalez-Ericsson, L Formisano, ... Cancer Research 84 (9_Supplement), PS03-04-PS03-04, 2024 | | 2024 |
| A selective FGFR1/2 degrader overcomes endocrine resistance in ER+/FGFR1-amplified andFGFR1/2-mutant breast cancer Y Uemoto, CC Lin, B Wang, D Ye, E Bikorimana, A Servetto, L Formisano, ... Cancer Research 84 (6_Supplement), 3308-3308, 2024 | | 2024 |
| Combined inhibition of CDK4/6 and AKT is highly active against the luminal androgen receptor (LAR) subtype of triple negative breast cancer (TNBC) R Chica-Parrado, GM Kim, Y Uemoto, D Ye, F Napolitano, CC Lin, ... Cancer Research 84 (6_Supplement), 7592-7592, 2024 | | 2024 |
